期刊文献+

希罗达治疗晚期胃癌和乳腺癌42例疗效分析 被引量:1

下载PDF
导出
摘要 目的:观察希罗达对晚期胃癌和乳腺癌的疗效和毒副反应。方法:采用希罗达治疗42例晚期胃癌或乳腺癌患者,希罗达剂量为2500mg/(m2·d),分两次口服,d1~d14,每3周为1个周期,至少化疗2个周期后评价疗效,(CR+PR)为有效。结果:42例患者全部可评价疗效,其中CR2例,PR8例。总有效率(CR+PR)为23.8%。患者中位疾病进展时间为6.5个月。主要毒性作用为手足综合征,其他有恶心呕吐、皮肤色素沉着、腹泻。结论:希罗达对晚期胃癌和乳腺癌疗效好,毒副反应小。
出处 《中国医药导报》 CAS 2007年第06S期51-51,共1页 China Medical Herald
  • 相关文献

参考文献2

二级参考文献21

  • 1孙燕.抗肿瘤新药的临床试用方法[J].中华肿瘤杂志,1980,2:150-150.
  • 2Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 3Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 4Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 5Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 6Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 7Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 8Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 9Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 10O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.

共引文献74

同被引文献11

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部